Strategy and planning for chemopreventive drug development: clinical development plans II
- PMID: 9154168
- DOI: 10.1002/jcb.240630705
Strategy and planning for chemopreventive drug development: clinical development plans II
Abstract
This is the second publication of Clinical Development Plans from the National Cancer Institute, Division of Cancer Prevention and Control, Chemoprevention Branch and Agent Development Committee. The Clinical Development Plans summarize the status of promising chemopreventive agents regarding evidence for safety and chemopreventive efficacy in preclinical and clinical studies. They also contain the strategy for further development of these drugs, addressing pharmacodynamics, drug effect measurements, intermediate biomarkers for monitoring efficacy, toxicity, supply and formulation, regulatory approval, and proposed clinical trials. Sixteen new Clinical Development Plans are presented here: curcumin, dehydroepiandrosterone, folic acid, genistein, indole-3-carbinol, perillyl alcohol, phenethyl isothiocyanate, 9-cis-retinoic acid, 13-cis-retinoic acid, l-selenomethionine and 1, 4-phenylenebis(methylene)selenocyanate, sulindac sulfone, tea, ursodiol, vitamin A, and (+)-vorozole. The objective of publishing these plans is to stimulate interest and thinking among the scientific community on the prospects for developing these and future generations of chemopreventive drugs.
Similar articles
-
New agents for cancer chemoprevention.J Cell Biochem Suppl. 1996;26:1-28. doi: 10.1002/jcb.240630703. J Cell Biochem Suppl. 1996. PMID: 9154166 Review.
-
Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.J Cell Biochem Suppl. 1994;20:55-62. doi: 10.1002/jcb.240560906. J Cell Biochem Suppl. 1994. PMID: 7616753
-
Progress in cancer chemoprevention.Ann N Y Acad Sci. 1999;889:1-13. doi: 10.1111/j.1749-6632.1999.tb08718.x. Ann N Y Acad Sci. 1999. PMID: 10668477 Review.
-
Effects of 1,4-phenylenebis(methylene)selenocyanate, phenethyl isothiocyanate, indole-3-carbinol, and d-limonene individually and in combination on the tumorigenicity of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung.Anticancer Res. 1996 Sep-Oct;16(5A):2709-12. Anticancer Res. 1996. PMID: 8917375
-
Multiorgan sensitivity to anticarcinogenesis by the organoselenium 1,4-phenylenebis(methylene)selenocyanate.Nutr Cancer. 2001;40(1):18-27. doi: 10.1207/S15327914NC401_6. Nutr Cancer. 2001. PMID: 11799918 Review.
Cited by
-
Low-dose curcumin enhances hippocampal neurogenesis and memory retention in young mice.Arch Pharm Res. 2023 May;46(5):423-437. doi: 10.1007/s12272-023-01440-7. Epub 2023 Mar 22. Arch Pharm Res. 2023. PMID: 36947339
-
Comparative Pharmacokinetic of Curcuminoids Formulations with an Omega-3 Fatty Acids Monoglyceride Carrier: A Randomized Cross-Over Triple-Blind Study.Nutrients. 2022 Dec 16;14(24):5347. doi: 10.3390/nu14245347. Nutrients. 2022. PMID: 36558506 Free PMC article. Clinical Trial.
-
Monitoring of the Surface Charge Density Changes of Human Glioblastoma Cell Membranes upon Cinnamic and Ferulic Acids Treatment.Int J Mol Sci. 2020 Sep 22;21(18):6972. doi: 10.3390/ijms21186972. Int J Mol Sci. 2020. PMID: 32971943 Free PMC article.
-
Enhanced anti-hepatoma effect of a novel curcumin analog C086 via solid dispersion technology.Drug Deliv. 2020 Dec;27(1):927-937. doi: 10.1080/10717544.2020.1785051. Drug Deliv. 2020. PMID: 32597247 Free PMC article.
-
Eight Weeks of a High Dose of Curcumin Supplementation May Attenuate Performance Decrements Following Muscle-Damaging Exercise.Nutrients. 2019 Jul 23;11(7):1692. doi: 10.3390/nu11071692. Nutrients. 2019. PMID: 31340534 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical